Anne has over 25 years’ experience in pharma and biotech, having most recently served as the Chief Scientific Officer at BenevolentAI, working to maximize the value of AI/ML technologies to enhance and accelerate the end-to-end drug discovery process. Prior to that, Anne worked for Pfizer for over 15 years, where she led technology platform teams and drug discovery programs from early discovery through to clinical development across a range of therapeutic areas, including cardiovascular, pain, allergy & respiratory, genitourinary and neurodegeneration. She was latterly Head of Pharmacology and COO for Pfizer Neusentis, focused on research into Pain and Sensory Disorders. Throught her career, Anne has focused on target identification, pre-clinical portfolio management, technology investment across a wide range of target classes and therapeutic modalities, Anne joined GSK in Jan 2025 as SVP Head of Target Discovery.
PROUD SIGNATORIES
We invest in talented innovators. We strongly adhere to the view that diversity, including under-represented groups, strongly adds to success. If you are an entrepreneur seeking investment and a partner who can help you to build your business, we would love to hear from you. Please get in contact with our team.